Did you know there is a pivotal Phase 3 clinical study available to early stage (IA, IB, IIA) MF patients currently enrolling participants throughout the United States?
The Fluorescent Light Activated Synthetic Hypericin (FLASH) Study is open for the treatment of mycosis fungoides. Read more about this novel new approach to light therapy in the attached article.
One of the critical ways we, as patients, can contribute to the advancement of research and science in cutaneous lymphoma is to volunteer to participate in a clinical study.
Phase III clinical trials are hard to fill because they require a large number of participants (over 100). In a rare disease like cutaneous lymphoma, this can be very challenging. It is the last phase of the clinical trial process before submitting the data to the FDA for final approval and commercial availability.
A special pilot program is being considered for patients who live in Texas and Louisiana. In order to determine if satellite centers can be opened to provide easier access for people participating in the study, we invite you to answer this brief survey. It will help the company find new locations for delivering the treatments.
Click here to take the survey:
You can view the specifics about the study on our website:
Or on the Clinical Trials government website:
Take advantage of the chance to play the most important role in advancing medical knowledge about mycosis fungoides. Your participation can help make new therapies available to people around the world living with cutaneous lymphoma.
Let’s do our part!
Thank you for your time and consideration.
| 
